Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age12-17
SponsorExelixis
About this trial
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Eligibility criteria
Qualifiers
Participants must be < 17 years old.
Participants must have a minimum body weight of ≥ 10 kilograms (kg) at enrollment.
Performance status of ≥ 50% as measured by Lansky for participants < 16 years of age or Karnofsky for participants ≥ 16 years of age.
Have a relapsed or refractory solid tumor, including primary CNS tumors (excluding lymphoma).
Disqualifiers
For participants with CNS primary tumors, evidence of intracranial or intratumoral hemorrhage are excluded.
Diagnosis of lymphoma.
Lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.
Trial design
Treatments tested in this trial
- Zanzalintinib
Treatment groups
18 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov